Diaceutics (DXRX) Price & Analysis

Compare

10 Followers

DXRX Stock Chart & Stats

161.50p

0.50p(0.34%)

At close: Jan 09 4:00 PM EST

161.50p

0.50p(0.34%)

Day’s Range― - ―

52-Week Range106.00p - 168.00p

Previous CloseN/A

Volume29.93K

Average Volume (3M)98.94K

Market Cap

£138.74M

Enterprise Value90.09M

Total Cash (Recent Filing)£10.38M

Total Debt (Recent Filing)£1.13M

Price to Earnings (P/E)―

Beta0.49

Next Earnings

Mar 24, 2026

EPS Estimate

0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding84,900,730

10 Day Avg. Volume75,834

30 Day Avg. Volume98,941

Financial Highlights & Ratios

PEG Ratio25.77

Price to Book (P/B)2.66

Price to Sales (P/S)3.30

P/FCF Ratio-26.62

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£224.94

Price Target Upside39.28% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)1.77

Revenue Forecast (FY)£3.98B

Bulls Say, Bears Say

Bulls Say

Contract NegotiationDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.

Revenue GrowthAnother year of strong organic revenue growth in FY24 (+36% to £32.2m) and continued momentum into the first four months of 2025 (+35% to £8.4m), puts the business well on track to deliver on current revenue (+25%) and EBITDA expectations for FY25.

Strategic PartnershipsDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, and during FY24 Diaceutics worked with 85 therapies across 52 customers.

Bears Say

Share Price VolatilityAnalyst sees the recent share pullback as a buying opportunity due to the business delivering very strong organic growth and trading on just 2.3x current FY25E EV/sales, despite its superior top-line growth.

Diaceutics News

Diaceutics PLC Enhances Employee Engagement with Share Incentive Plan

Diaceutics ( ($GB:DXRX) ) has shared an update. Diaceutics PLC has announced that its trustees have purchased ordinary...

5d ago

Diaceutics Enhances Employee Incentives with Share Purchases

Diaceutics ( ($GB:DXRX) ) has issued an announcement. Diaceutics PLC has announced the purchase of ordinary shares by...

1M ago

Diaceutics Plc Reports Strong H1 2025 Performance

Diaceutics Plc ( ($DIUXF) ) has released its Q2 earnings. Here is a breakdown of the information Diaceutics...

2M ago

Diaceutics PLC Reports Strong H1 2025 Results, On Track for Profitability

Diaceutics ( ($GB:DXRX) ) has shared an announcement. Diaceutics PLC reported strong financial results for the first half...

2M ago

Diaceutics to Announce Half-Year Results and Host Investor Webinar

Diaceutics ( ($GB:DXRX) ) has provided an update. Diaceutics PLC announced it will release its unaudited half-year results...

2M ago

Diaceutics PLC Expands Share Incentive Plan with New Share Issuance

Diaceutics ( ($GB:DXRX) ) just unveiled an announcement. Diaceutics PLC has announced that Global Shares Trustees (UK) Limited...

2M ago

Diaceutics to Present at Canaccord Genuity Growth Conference

Diaceutics ( ($GB:DXRX) ) has issued an update. Diaceutics PLC announced its participation in the Canaccord Genuity 45th...

3M ago

Diaceutics Enhances Employee Incentives with Share Purchase Plan

The latest update is out from Diaceutics ( ($GB:DXRX) ). Diaceutics PLC has announced the purchase of ordinary...

3M ago

Diaceutics Appoints Lauren DeWitt as General Counsel

Diaceutics ( ($GB:DXRX) ) just unveiled an update. Diaceutics PLC has appointed Lauren DeWitt as Executive Vice President,...

3M ago

Diaceutics PLC Issues Share Options to Key Personnel

Diaceutics ( ($GB:DXRX) ) just unveiled an update. Diaceutics PLC has announced the issuance of 1,886,357 share options...

4M ago

Diaceutics price target raised to 195 GBp from 165 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics (DIUXF) to 195 GBp from 165...

9M ago

Diaceutics price target raised to 165 GBp from 145 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics to 165 GBp from 145 GBp...

1y ago

DXRX FAQ

What was Diaceutics Plc’s price range in the past 12 months?

Diaceutics Plc lowest share price was 106.00p and its highest was 168.00p in the past 12 months.

What is Diaceutics Plc’s market cap?

Diaceutics Plc’s market cap is £138.74M.

When is Diaceutics Plc’s upcoming earnings report date?

Diaceutics Plc’s upcoming earnings report date is Mar 24, 2026 which is in 135 days.

How were Diaceutics Plc’s earnings last quarter?

Diaceutics Plc released its earnings results on Sep 23, 2025. The company reported -0.028p earnings per share for the quarter, the consensus estimate of -0.028p by 0p.

Is Diaceutics Plc overvalued?

According to Wall Street analysts Diaceutics Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Diaceutics Plc pay dividends?

Diaceutics Plc does not currently pay dividends.

What is Diaceutics Plc’s EPS estimate?

Diaceutics Plc’s EPS estimate is 0.05.

How many shares outstanding does Diaceutics Plc have?

Diaceutics Plc has 84,900,730 shares outstanding.

What happened to Diaceutics Plc’s price movement after its last earnings report?

Diaceutics Plc reported an EPS of -0.028p in its last earnings report, expectations of -0.028p. Following the earnings report the stock price went up 4.605%.

Which hedge fund is a major shareholder of Diaceutics Plc?

Currently, no hedge funds are holding shares in GB:DXRX

Company Description

Diaceutics Plc

Diaceutics (DXRX) is a data analytics and technology company specializing in precision medicine and diagnostics. The company operates primarily in the healthcare sector, providing solutions that enhance the development and commercialization of targeted therapies. Diaceutics offers a comprehensive platform that integrates diagnostic data, patient insights, and real-world evidence, enabling pharmaceutical companies to optimize their strategies in personalized medicine, improve patient outcomes, and streamline the diagnostic journey.

Diaceutics (DXRX) Earnings & Revenues

Historic Earnings Reports

DXRX Stock 12 Month Forecast

Average Price Target

224.94p

▲(39.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"115":"115p","170":"170p","225":"225p","142.5":"142.5p","197.5":"197.5p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":224.94110632,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">224.94p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":224.94110632,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">224.94p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":224.94110632,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">224.94p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[115,142.5,170,197.5,225],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Feb<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165,169.6108543323077,174.2217086646154,178.83256299692306,183.44341732923075,188.05427166153845,192.66512599384615,197.27598032615384,201.88683465846154,206.49768899076923,211.1085433230769,215.7193976553846,220.3302519876923,{"y":224.94110632,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165,169.6108543323077,174.2217086646154,178.83256299692306,183.44341732923075,188.05427166153845,192.66512599384615,197.27598032615384,201.88683465846154,206.49768899076923,211.1085433230769,215.7193976553846,220.3302519876923,{"y":224.94110632,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165,169.6108543323077,174.2217086646154,178.83256299692306,183.44341732923075,188.05427166153845,192.66512599384615,197.27598032615384,201.88683465846154,206.49768899076923,211.1085433230769,215.7193976553846,220.3302519876923,{"y":224.94110632,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":132.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >